Evidence map›Paper›PMID 24656978›Full record

ReviewMolecular oncology2014

The validity of circulating microRNAs in oncology: five years of challenges and contradictions.

J Jarry, D Schadendorf, C Greenwood, A Spatz, L C van Kempen

Abstract readEvaluation StudyReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Review
  7. Liquid biopsies in cancer.Molecular biomedicine · 2025
    Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

J JarryLady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
D SchadendorfDepartment of Dermatology, University Hospital Essen, Germany.
C GreenwoodLady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada; Department of Human Genetics, McGill University, Montreal, QC, Canada; Department of Oncology, McGill University, Montreal, QC, Canada; Department of Pathology, McGill University, Montreal, QC, Canada.
A SpatzLady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada; Department of Pathology, Jewish General Hospital, Montreal, QC, Canada; Department of Oncology, McGill University, Montreal, QC, Canada; Department of Pathology, McGill University, Montreal, QC, Canada.
L C van KempenLady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada; Department of Pathology, Jewish General Hospital, Montreal, QC, Canada; Department of Pathology, McGill University, Montreal, QC, Canada. Electronic address: Leon.vankempen@mcgill.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs (miRNAs) in circulation have received an increasing amount of interest as potential minimal invasive diagnostic tools in oncology. Several diagnostic, prognostic and predictive signatures have been proposed for a variety of cancers at different stages of disease, but these have not been subjected to a critical review regarding their validity: reproducible identification in comparable studies and/or with different platforms of miRNA detection. In this review, we will critically address the results of circulating miRNA research in oncology that have been published between January 2008 and June 2013 (5.5 years), and discuss pre-analytical challenges, technological pitfalls and limitations that may contribute to the non-reproducibility of circulating miRNA research.

Indexed as

Blood Chemical AnalysisBiomarkers, TumorHumansMedical OncologyMicroRNAsNeoplasmsPolymerase Chain ReactionPrognosisReproducibility of ResultsTranscriptomeBiomarkers, TumorMicroRNAsCirculating microRNAsDiagnostic toolMeta-analysisOncology

Identifiers

PMID24656978
PMCPMC5528532

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.